Stacy C. Dilzer

1.6k total citations
25 papers, 1.3k citations indexed

About

Stacy C. Dilzer is a scholar working on Endocrinology, Diabetes and Metabolism, Epidemiology and Oncology. According to data from OpenAlex, Stacy C. Dilzer has authored 25 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Endocrinology, Diabetes and Metabolism, 7 papers in Epidemiology and 6 papers in Oncology. Recurrent topics in Stacy C. Dilzer's work include Diabetes Treatment and Management (8 papers), Peptidase Inhibition and Analysis (6 papers) and Neuroendocrine Tumor Research Advances (4 papers). Stacy C. Dilzer is often cited by papers focused on Diabetes Treatment and Management (8 papers), Peptidase Inhibition and Analysis (6 papers) and Neuroendocrine Tumor Research Advances (4 papers). Stacy C. Dilzer collaborates with scholars based in United States, Switzerland and Spain. Stacy C. Dilzer's co-authors include Kenneth C. Lasseter, Gary Herman, Arthur Bergman, John A. Wagner, David L. Ebel, Li Chen, Wei Zeng, Julie A. Stone, Elizabeth Migoya and Patrick Larson and has published in prestigious journals such as Annals of Internal Medicine, Antimicrobial Agents and Chemotherapy and Clinical Pharmacology & Therapeutics.

In The Last Decade

Stacy C. Dilzer

25 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stacy C. Dilzer United States 18 446 382 255 253 252 25 1.3k
Diane K. Jorkasky United States 27 350 0.8× 144 0.4× 353 1.4× 341 1.3× 57 0.2× 68 1.7k
Atef Halabi Germany 25 436 1.0× 242 0.6× 306 1.2× 505 2.0× 49 0.2× 79 2.2k
Yi Huan China 21 401 0.9× 177 0.5× 259 1.0× 700 2.8× 1.3k 5.0× 68 2.7k
James E. Patrick United States 20 124 0.3× 184 0.5× 269 1.1× 277 1.1× 136 0.5× 50 1.4k
Thomas Gießmann Germany 19 219 0.5× 123 0.3× 216 0.8× 246 1.0× 147 0.6× 33 1.9k
Srijib Goswami United States 12 208 0.5× 199 0.5× 153 0.6× 307 1.2× 98 0.4× 18 830
Elizabeth K. Hussey United States 19 289 0.6× 85 0.2× 165 0.6× 247 1.0× 295 1.2× 39 983
Klaus Kutz Switzerland 21 178 0.4× 220 0.6× 320 1.3× 297 1.2× 69 0.3× 59 1.8k
Wen Chyi Shyu United States 23 92 0.2× 501 1.3× 88 0.3× 408 1.6× 170 0.7× 78 1.6k
Adithan Chandrasekaran India 20 182 0.4× 148 0.4× 99 0.4× 216 0.9× 62 0.2× 73 1.2k

Countries citing papers authored by Stacy C. Dilzer

Since Specialization
Citations

This map shows the geographic impact of Stacy C. Dilzer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stacy C. Dilzer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stacy C. Dilzer more than expected).

Fields of papers citing papers by Stacy C. Dilzer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stacy C. Dilzer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stacy C. Dilzer. The network helps show where Stacy C. Dilzer may publish in the future.

Co-authorship network of co-authors of Stacy C. Dilzer

This figure shows the co-authorship network connecting the top 25 collaborators of Stacy C. Dilzer. A scholar is included among the top collaborators of Stacy C. Dilzer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stacy C. Dilzer. Stacy C. Dilzer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lasseter, Kenneth C., et al.. (2013). Evaluation of the Single-dose Pharmacokinetics of Bilastine in Subjects with Various Degrees of Renal Insufficiency. Clinical Drug Investigation. 33(9). 665–673. 28 indexed citations
2.
Lasseter, Kenneth C., et al.. (2012). Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers. Pulmonary Pharmacology & Therapeutics. 25(2). 193–199. 23 indexed citations
3.
Lasseter, Kenneth C., Stacy C. Dilzer, Josep M. Jansat, et al.. (2011). Safety And Pharmacokinetics Of Multiple Doses Of Aclidinium Bromide Administered Twice Daily In Healthy Volunteers. A1615–A1615. 3 indexed citations
4.
He, Yanling, Ron Sabo, Joelle Campestrini, et al.. (2007). The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin. European Journal of Clinical Pharmacology. 63(7). 677–686. 58 indexed citations
5.
Bergman, Arthur, Goutam C. Mistry, Wen‐Lin Luo, et al.. (2007). Dose‐proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase‐4 inhibitor, in healthy volunteers. Biopharmaceutics & Drug Disposition. 28(6). 307–313. 14 indexed citations
6.
Vincent, Stella, James R. Reed, Arthur Bergman, et al.. (2007). Metabolism And Excretion of the Dipeptidyl Peptidase 4 Inhibitor [14C]Sitagliptin in Humans. Drug Metabolism and Disposition. 35(4). 533–538. 127 indexed citations
7.
Lasseter, Kenneth C., Stacy C. Dilzer, & Neila Smith. (2007). Intravenous conivaptan: Effects on the QTc interval and other electrocardiographic parameters in healthy volunteers. Advances in Therapy. 24(2). 310–318. 2 indexed citations
8.
Mistry, Goutam C., Elizabeth Migoya, Paul Deutsch, et al.. (2007). Single‐ and Multiple‐Dose Administration of Caspofungin in Patients With Hepatic Insufficiency: Implications for Safety and Dosing Recommendations. The Journal of Clinical Pharmacology. 47(8). 951–961. 49 indexed citations
9.
Bergman, Arthur, David L. Ebel, Fang Liu, et al.. (2007). Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase‐4 inhibitor, in healthy volunteers. Biopharmaceutics & Drug Disposition. 28(6). 315–322. 70 indexed citations
10.
Herman, Gary, Arthur Bergman, Fang Liu, et al.. (2006). Pharmacokinetics and Pharmacodynamic Effects of the Oral DPP‐4 Inhibitor Sitagliptin in Middle‐Aged Obese Subjects. The Journal of Clinical Pharmacology. 46(8). 876–886. 146 indexed citations
11.
Stevens, C. Melinda, Arthur Bergman, Wen‐Lin Luo, et al.. (2006). PII-49Lack of clinically significant effect of moderate hepatic insufficiency on the pharmacokinetics of MK-0431 (sitagliptin), a dipeptidyl-peptidase-IV (DPP-IV) inhibitor. Clinical Pharmacology & Therapeutics. 79(2). P49–P49. 10 indexed citations
12.
Turncliff, Ryan Z., Joi Dunbar, Qunming Dong, et al.. (2005). Pharmacokinetics of Long‐Acting Naltrexone in Subjects With Mild to Moderate Hepatic Impairment. The Journal of Clinical Pharmacology. 45(11). 1259–1267. 24 indexed citations
13.
Kovarik, John M., et al.. (2005). FTY720 Pharmacokinetics in Mild to Moderate Hepatic Impairment. The Journal of Clinical Pharmacology. 45(4). 446–452. 17 indexed citations
14.
Lasseter, Kenneth C., Stacy C. Dilzer, Ramón Vargas, Scott A. Waldman, & Robert J. Noveck. (2004). Pharmacokinetics and Safety of Ebastine in Patients with Impaired Hepatic Function Compared with Healthy Volunteers. Clinical Pharmacokinetics. 43(2). 121–129. 14 indexed citations
15.
Stone, Julie A., Xin Xu, Gregory A. Winchell, et al.. (2004). Disposition of Caspofungin: Role of Distribution in Determining Pharmacokinetics in Plasma. Antimicrobial Agents and Chemotherapy. 48(3). 815–823. 111 indexed citations
16.
Agrawal, Nancy, Mark J. Rose, Catherine Z. Matthews, et al.. (2003). Pharmacokinetics of Etoricoxib in Patients with Hepatic Impairment. The Journal of Clinical Pharmacology. 43(10). 1136–1148. 19 indexed citations
17.
Stone, JA, Peter Wickersham, Paul Deutsch, et al.. (2001). Drug interactions between caspofungin and tacrolimus. 41. 1. 17 indexed citations
18.
Wickersham, Peter, Paul Deutsch, Gregory A. Winchell, et al.. (2001). Effect of hepatic insufficiency on the pharmacokinetics of caspofungin. 41. 1. 12 indexed citations
19.
Prueksaritanont, Thomayant, José María Guerrero Vega, Jamie J. Zhao, et al.. (2001). Interactions between Simvastatin and Troglitazone or Pioglitazone in Healthy Subjects. The Journal of Clinical Pharmacology. 41(5). 573–581. 47 indexed citations
20.
Smith, Deborah A., et al.. (1998). Pharmacokinetics and Pharmacodynamics of Zolmitriptan in Patients with Mild to Moderate Hypertension: A Double‐Blind, Placebo‐Controlled Study. The Journal of Clinical Pharmacology. 38(8). 685–693. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Diane K. Jorkasky Breakdown of academic impact, for papers by Atef Halabi Breakdown of academic impact, for papers by Yi Huan Breakdown of academic impact, for papers by James E. Patrick Breakdown of academic impact, for papers by Thomas Gießmann Breakdown of academic impact, for papers by Srijib Goswami Breakdown of academic impact, for papers by Elizabeth K. Hussey Breakdown of academic impact, for papers by Klaus Kutz Breakdown of academic impact, for papers by Wen Chyi Shyu Breakdown of academic impact, for papers by Adithan Chandrasekaran
Rankless by CCL
2026